cytarabine has been researched along with Disease Exacerbation in 160 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.63) | 18.7374 |
| 1990's | 24 (15.00) | 18.2507 |
| 2000's | 75 (46.88) | 29.6817 |
| 2010's | 52 (32.50) | 24.3611 |
| 2020's | 8 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bi, Y; Cheng, X; Cui, H; Cui, Y; Gao, Y; Guo, M; Kong, P; Li, H; Liu, F; Ma, Y; Niu, X; Qian, Y; Wang, F; Xu, J; Yan, T; Yang, J; Zhang, L; Zhang, X | 1 |
| Ben Khoud, M; Brinster, C; Figeac, M; Leprêtre, F; Mopin, A; Quesnel, B; Sebda, S; Villenet, C | 1 |
| Boudreau, LH; Gharib, E; Pichaud, N; Robichaud, GA; Veilleux, V | 1 |
| Beham-Schmid, C; Deutsch, A; Greinix, H; Hatzl, S; Neumeister, P; Pichler, M; Posch, F; Prochazka, KT; Stöger, H | 1 |
| Baumann, T; Caballero, AC; Canet, M; Escoda, L; García, O; Iserte, L; López-Guillermo, A; Magnano, L; Mercadal, S; Muntañola, A; Salar, A; Sánchez-González, B; Sancho, JM; Soler, A; Sorigué, M; Villalobos, MT | 1 |
| Lin, N; Wang, L | 1 |
| Arasaretnam, A; Bishton, M; Bolam, S; Creasey, T; Crosbie, N; Dawi, S; Dutton, D; Eyre, TA; Follows, G; Goradia, H; Harrison, S; Johnston, R; Kirkwood, AA; Lambert, J; Lewis, D; McCulloch, R; McKay, P; McMillan, A; Miles, O; Osborne, W; Patmore, R; Phillips, N; Robinson, A; Rule, S; Wilson, MR | 1 |
| Guerra, R; Saavedra, AP; Yi, LG | 1 |
| Balleari, E; Bernal, T; Beyne-Rauzy, O; Bordessoule, D; Calabuig, M; Cametti, G; Campelo, MD; Cheze, S; Cony-Makhoul, P; Dreyfus, F; Fenaux, P; Fensterl, J; Ferrero, D; Gaidano, G; Germing, U; Gioia, D; Götze, K; Guerci-Bresler, A; Hamel, JF; Kaivers, J; Kelaidi, C; Komrokji, R; Kotsianidis, I; Müller-Thomas, C; Pane, F; Park, S; Ramos, F; Roboz, GJ; Rose, C; Sanna, A; Santini, V; Sanz, GF; Sapena, R; Sekeres, MA; Stamatoullas, A; Steensma, DP; Thépot, S; Toma, A; Vey, N; Wattel, E | 1 |
| Balakrishnan, VS | 1 |
| Bosi, A; Coltro, G; Guglielmelli, P; Mannelli, F; Pacilli, A; Vannucchi, AM | 1 |
| Bai, X; Chen, Y; Ji, N; Liu, F; Liu, J; Liu, Y; Qian, J; Qiu, X; Sun, S; Sun, X; Wang, Y; Zhu, H | 1 |
| Guo, J; Parasramka, S; Rosenfeld, M; Talari, G; Villano, JL | 1 |
| Fares, E; Maddah, J; Mansour, MJ; Mokbel, E; Nasr, F | 1 |
| Aleem, E; Arceci, RJ; Azorsa, DO; Bista, R; Henry, MM; Lee, DW; Patel, AR; Wai, DH | 1 |
| Creutzig, U; de Haas, V; Flasinski, M; Klusmann, JH; Reinhardt, D; Reinhardt, K; Scheibke, K; van der Velden, VHJ; Verwer, F; von Neuhoff, C; Zimmermann, M; Zwaan, CM | 1 |
| Alvarez De Celis, I; Arcari, A; Chiappella, A; Cox, MC; Di Rocco, A; Dreyling, M; Evangelista, A; Fabbri, A; Ferrero, S; Finolezzi, E; Gentile, M; Gini, G; Hermine, O; Hohaus, S; Hoster, E; Loseto, G; Marino, D; Martelli, M; Merli, M; Molinari, AL; Morello, L; Nassi, L; Pelosini, M; Perrone, T; Piazza, F; Puccini, B; Re, A; Ruggeri, M; Sciarra, R; Tecchio, C; Tisi, MC; Visco, C; Vitolo, U; Zilioli, VR; Zoellner, AK | 1 |
| Banck, JC; Görlich, D | 1 |
| Bishton, M; Campbell, R; Cheah, CY; Cochrane, T; De Mel Widanalage, S; Gilbertson, M; Hapgood, G; Hawkes, E; Hill, K; Johnston, A; Lee, HP; Manos, K; Nelson, N; Ng, M; Ng, ZY; Opat, S; Poon, M; Purtill, D; Ratnasingam, S; Ritchie, D; Schwarer, A; Seymour, J; Shorten, S; Sunny, T; Tam, C; Xin, L | 1 |
| Bo, J; Sun, L; Wang, Q; Yuan, L; Zhao, Y | 1 |
| Badoux, X; Jones, JA; Kantarjian, H; Keating, MJ; Kipps, TJ; O'Brien, S; Plunkett, W; Tsimberidou, AM; Wen, S; Wierda, WG | 1 |
| Go, A; Guo, R; Parthasarathy, M; Rodriguez, T; Smith, S; Sobol, U; Stiff, P; Vimr, R | 1 |
| Berdel, WE; Frey, K; Giovannoni, L; Gutbrodt, KL; Klapper, W; Neri, D; Pabst, T; Schliemann, C | 1 |
| Aramendía, JM; Carranza, OE; Castañón, E; Espinós, J; Fusco, JP; Gil-Bazo, I; Martín, P; Rodríguez, J; Santisteban, M; Zubiri, L | 1 |
| Fernández-Sojo, J; Oliveras Vilà, T; Ribera, JM; Vives, S | 1 |
| Abdulrezzak, U; Cetin, M; Kaynar, L; Keklik, M; Kontas, O; Sivgin, S | 1 |
| Baerlocher, GM; Dengler, J; Ehninger, G; Einsele, H; Fabarius, A; Falge, C; Haferlach, C; Hanfstein, B; Hasford, J; Hehlmann, R; Heim, D; Heimpel, H; Hochhaus, A; Hossfeld, DK; Kanz, L; Kneba, M; Kolb, HJ; Krause, SW; Lauseker, M; Müller, MC; Nerl, C; Neubauer, A; Pfirrmann, M; Pfreundschuh, M; Pletsch, N; Proetel, U; Saußele, S; Schnittger, S; Schreiber, A; Spiekermann, K; Stegelmann, F; Waller, CF | 1 |
| Anderson, CM; de Magalhaes Silverman, M; Hoffman, HT; Hoover, AC; Smith, MC; Syrbu, SI | 1 |
| Al Ali, NH; Bello, CM; Duong, VH; Fernandez, HF; Jaglal, MV; Komrokji, RS; Lancet, JE; List, AF; Padron, E | 1 |
| Tohyama, K | 1 |
| Belada, D; Berková, A; Bolomská, I; Burešová, L; Campr, V; Klener, P; Kozák, T; Kubáčková, K; Matuška, M; Pirnos, J; Přibylová, J; Pytlík, R; Sýkorová, A; Trněný, M; Vášová, I | 1 |
| Arzu, I; Dabaja, BS; Fayad, LE; Hagemeister, FB; Hess, K; Kedir, A; Mawlawi, O; Medeiros, LJ; Oki, Y; Podoloff, DA; Reed, VK; Rodriguez, A; Shihadeh, F; Wogan, CF | 1 |
| Berger, T; Di Pauli, F; Maier, H; Rhomberg, P; Steurer, M; Stockhammer, G; Uprimny, C; Walder, A | 1 |
| Al-Malki, H; Cebrian-Silla, A; Fehse, B; Fransen, NL; Garcia-Verdugo, JM; Gomez-Nicola, D; Perry, VH; Riecken, K; Suzzi, S; Vargas-Caballero, M | 1 |
| Hashida, R; Hatano, M; Hori, M; Nishida, H; Obara, K | 1 |
| Chen-Liang, TH; Florensa, L; Jerez, A; Ortuño, FJ | 1 |
| Akagi, T; Hofmann, WK; Jann, JC; Kato, M; Kawamata, N; Klaumünzer, M; Koeffler, HP; Liem, NL; Lock, RB; Marshall, GM; Mossner, M; Nowak, D; Nowak, V; Ogawa, S; Okamoto, R; Papa, RA; Sanada, M; Thoennissen, NH | 1 |
| Barriere, J; Borchiellini, D; Boscagli, A; Coso, D; Garnier, G; Gastaud, L; Gutnecht, J; Martin, N; Naman, H; Petit, E; Peyrade, F; Re, D; Rossignol, B; Saudes, L; Thyss, A | 1 |
| Acebo-Mariñas, E; Aperribay-Esparza, A; de Quintana-Sancho, A; Gardeazabal-García, J | 1 |
| Kato, T; Komiya, A; Kondo, F; Nomura, K; Wakisaka, M | 1 |
| Dou, MH; Hu, C; Huang, J; Jin, J; Li, Y; Lou, YJ; Luo, YW; Ma, LY; Mao, LP; Mei, C; Niu, LM; Ren, YL; Tong, HY; Wang, JH; Wei, JY; Xie, LL; Xu, GX; Ye, L; Ye, XN; Yu, WJ; Zhou, XP | 1 |
| Aulitzky, W; Baldus, CD; Berdel, WE; Bornhäuser, M; Brandts, CH; Burchert, A; Dürk, H; Ehninger, G; Einsele, H; Frickhofen, N; Geer, T; Giagounidis, A; Görner, M; Hänel, M; Hase, J; Heits, F; Herbst, R; Hüttmann, A; Illmer, T; Junghanß, C; Kaiser, U; Kiani, A; Klut, IM; Krämer, A; Kramer, M; Krause, SW; Krug, U; Kullmer, J; Kunzmann, V; Link, H; Mackensen, A; Müller-Tidow, C; Neubauer, A; Noppeney, R; Parmentier, S; Reichle, A; Repp, R; Röllig, C; Schäfer-Eckart, K; Schaich, M; Schetelig, J; Serve, H; Thiede, C; von Bonin, M | 1 |
| Ardeshna, K; Badat, M; Cheesman, S; D'Sa, S; Joshi, R; Lambert, J; Linch, D; Maciocia, P; Mohamedbhai, S; Pule, M | 1 |
| Fujisawa, S; Hagihara, M; Ishii, Y; Itabashi, M; Matsumoto, K; Motohashi, K; Numata, A; Yamamoto, W | 1 |
| Briones, J; Cantalapiedra, A; Díaz-López, A; Domingo-Domenech, E; Espeso, M; García, JF; García-Sanz, R; Jiménez, MJ; López, FJ; Martínez, C; Pérez-Ceballos, E; Rodriguez, MJ; Rodriguez-Calvillo, M; Sampol, A; Sureda, A; Terol, MJ | 1 |
| Chen, P; Chen, X; Chen, Z; Hu, J; Hua, X; Le, S; Li, J; Lin, Q; Liu, T; Luo, X; Ren, J; Yang, T; Yuan, X; Zhang, L; Zheng, H; Zheng, J; Zheng, X; Zheng, Z | 1 |
| Brower, V | 1 |
| Calliada, F; Castagnola, C; Corso, A; Lazzarino, M; Mangiacavalli, S; Varettoni, M; Zappasodi, P | 1 |
| Chamberlain, MC; Glantz, MJ | 1 |
| Ando, K; Kawada, H; Murayama, H; Nakamura, N; Ogawa, Y; Ohmachi, K; Suzuki, R; Tsuboi, K | 1 |
| Gang, M; Goldin, A; Kline, I; Sirica, A; Venditti, JM; Woodman, RJ | 1 |
| Cai, Y; Lin, L; Ling, JY; Sun, XF; Tong, GL; Xia, Y; Zhen, ZJ | 1 |
| Chang, C; He, Q; Li, X; Pu, Q; Song, L; Su, J; Wu, L; Xu, L; Zhang, X | 1 |
| Hackanson, B; Lübbert, M; Rückert, A | 1 |
| Czumbil, L; Gyánó, G; Iványi, JL; Marton, E; Plander, M; Tóth, C | 1 |
| Ballman, KV; Brown, PD; Carrero, XW; Colgan, JP; Fitch, TR; Gilbert, MR; Habermann, TM; Hawkins, RB; Kurtin, PJ; Laack, NN; Morton, RF; O'Fallon, JR; O'Neill, BP; Pajon, ER; Scheithauer, BW; Windschitl, HE | 1 |
| Alfonso, R; Miralles, J; Moragón, M; Onrubia, J; Pérez-Crespo, M; Requena, L; Sevila, A | 1 |
| Hirabayashi, K; Ishii, E; Koike, K; Nakamura, T; Saito, S; Sakashita, K; Shiohara, M; Takahashi, D; Tanaka, M; Yanagisawa, R | 1 |
| Batchelor, TT; Egerer, G; Engert, A; Herrlinger, U; Kowoll, A; Lamprecht, M; Linnebank, M; Patrij, K; Pels, H; Reiser, M; Schackert, G; Schlegel, U; Schmidt-Wolf, IG; Vogt-Schaden, M; Wätzel, L | 1 |
| Alonzo, TA; Arceci, RJ; Barnard, D; Doyle, J; Gamis, AS; Gerbing, RB; Hilden, JM; Loew, TW; Massey, G; Perentesis, J; Ravindranath, Y; Sharma, M; Smith, FO; Sorrell, AD; Taub, J | 1 |
| Chae, YS; Kang, BW; Kim, JG; Lee, SJ; Lee, YJ; Moon, JH; Sohn, SK; Suh, JS | 1 |
| Holodny, A; Omuro, A; Palomba, ML; Pentsova, E; Rosenblum, M | 1 |
| Kimoto, Y; Moritake, H; Nunoi, H; Sawa, D; Shimonodan, H; Yamada, A | 1 |
| Baerlocher, GM; Branford, S; Dengler, J; Einsele, H; Erben, P; Fabarius, A; Falge, C; Göhring, G; Haferlach, C; Hänel, M; Hanfstein, B; Hasford, J; Hehlmann, R; Hochhaus, A; Hofmann, WK; Hughes, TP; Kanz, L; Kneba, M; Kolb, HJ; Krause, SW; Lauseker, M; Müller, MC; Neubauer, A; Pfirrmann, M; Pfreundschuh, M; Proetel, U; Saußele, S; Schnittger, S; Schubert, J; Spiekermann, K; Stegelmann, F; Waller, CF | 1 |
| Audet, JN; Gowing, G; Julien, JP; Paradis, R; Soucy, G | 1 |
| Chamberlain, MC | 2 |
| Ritchie, EK | 1 |
| Brychtova, Y; Chovancova, J; Doubek, M; Francova, HS; Horky, O; Krejci, M; Mayer, J; Navratil, M; Pospisilova, S; Stehlikova, O; Tichy, B; Tomiska, M | 1 |
| Aiken, R; Baidas, S; Batchelor, T; Cohn, A; Fulton, D; Gilbert, M; Gutheil, JC; Heros, D; Howell, SB; Jaeckle, KA; Kennedy, JM; Lesser, G; Mason, W; Moots, P; New, P; O'Day, SJ; Phuphanich, S; Rogers, L; Russell, C; Swinnen, LJ; Wong, E | 1 |
| Byrne, J; Carter, GI; Craddock, CF; Cull, GM; Garg, M; Haynes, AP; Lui Yin, JA; Lush, RJ; Mahendra, P; Mufti, G; Pagliuca, A; Parker, JE; Potter, MN; Prentice, HG; Russell, NH | 1 |
| de Fabritiis, P; De Propris, MS; Foa, R; Gentile, M; Giammartini, E; Giannarelli, D; Mandelli, F; Mauro, FR; Meloni, G; Rapanotti, MC | 1 |
| Carella, A; de Elvira, CR; Goldstone, AH; Mackinnon, S; Robinson, SP; Russell, N; Schmitz, N; Taghipour, G | 1 |
| Breitenbuecher, F; Fischer, T; Gamm, H; Gschaidmeier, H; Hess, G; Huber, C; Kindler, T; Kirkpatrick, CJ; Marx, A | 1 |
| Henderson, RD; Nicol, AJ; Rajah, T; Read, SJ | 1 |
| Baccarani, M; Bolton, AE; Capdeville, R; Cervantes, F; Cornelissen, JJ; Druker, BJ; Fischer, T; Gathmann, I; Goldman, JM; Gratwohl, A; Guilhot, F; Hochhaus, A; Hughes, T; Kantarjian, H; Larson, RA; Lechner, K; Nielsen, JL; O'Brien, SG; Reiffers, J; Rousselot, P; Saglio, G; Shepherd, J; Simonsson, B; Taylor, K; Verhoef, G | 1 |
| Lauterbach, I; Mann, G; Niemeyer, C; Parwaresch, R; Reiter, A; Riehm, H; Schrappe, M; Seidemann, K; Simonitsch, I; Stankewitz, K; Tiemann, M; Zimmermann, M | 1 |
| Deininger, MW; O'Brien, SG | 1 |
| Chamberlain, MC; Cole, BF; Glantz, MJ; Jaeckle, KA; Mackowiak, JI | 1 |
| Higa, T; Imai, A; Imamura, M; Kasai, M; Kiyama, Y; Kobayashi, N; Kondo, Y; Miyokawa, N; Ogasawara, M; Ogawa, T; Sato, K; Tanaka, J; Toubai, T | 1 |
| Davidson, KL; Devaney, MB; Dunlop, DJ; Johnson, PR; Mackie, MJ; Rogers, SY; Thomas, RV; Tighe, JE | 1 |
| Berger, U; Hehlmann, R | 1 |
| Abrey, LE; DeAngelis, LM; Lai, R; Rosenblum, MK | 1 |
| Abrahams, A; Eggener, SE; Keeler, TC | 1 |
| Elinder, G; Kimby, E; Sverrisdottir, A | 1 |
| Boccadoro, M; Campa, E; Campana, S; Dellacasa, C; Ferrero, D; Foli, C | 1 |
| Goldschmidt, N; Gural, A; Kornberg, A; Paltiel, O; Shopen, A; Spectre, G | 1 |
| Buesche, G; Buhr, T; Fonatsch, C; Freund, M; Ganser, A; Georgii, A; Hasford, J; Hecker, H; Hehlmann, R; Heimpel, H; Heinze, B; Holgado, S; Kreipe, HH; Pfirrmann, M; Schmeil, A; Tobler, A | 1 |
| Bogdahn, U; Hans, VH; Hau, P; Kleiter, I; Marienhagen, J; Schuierer, G; Schütz, H; Steinbrecher, A | 1 |
| Caballero, MD; Cañizo, MC; López-Holgado, N; Martín, A; Mateos, MV; Miguel, JF; Pérez-Simón, JA | 1 |
| Cabras, A; Carlo-Stella, C; Devizzi, L; Di Nicola, M; Gandola, L; Gianni, AM; Guidetti, A; Magni, M; Mariotti, J; Massimino, M; Matteucci, P | 1 |
| Aloulou, S; Cainap, C; Carde, P; Chalhoub, B; Fermé, C; Jabbour, E; Ribrag, V; Suzan, F; Toumi, N | 1 |
| Acquatella, G; Carneiro, M; García, R; Gómez, R; Hernández, M; Insausti, CL; Nouel, A; Santos, S | 1 |
| Delarue, R; Delmer, A; Hermine, O; Lefrère, F; Levy, V; Varet, B | 1 |
| Aydin, F; Bektas, O; Kavgaci, H; Ozdemir, F; Yavuz, AA; Yavuz, MN; Yilmaz, M | 1 |
| Bachelez, H; Brice, P; Dubertret, L; Dupuy, A; Janin, A; Lebbé, C; Mebazaa, A; Morel, P; Moulonguet, I; Mouly, F; Rivet, J; Rybojad, M; Vignon-Pennamen, MD | 1 |
| Boula, AM; Christoforidou, AV; Foudoulakis, AM; Mantadakis, E; Samonis, G; Xilouri, IM | 1 |
| Glasmacher, A; Gorschlüter, M; Mey, U; Schmidt-Wolf, IG; Schwerdtfeger, R | 1 |
| Irving, I; Kennedy, GA; McCarthy, C; Perel, JM; Walker, O; Williams, B | 1 |
| Albitar, M; Cahill, A; Cortes, J; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Gerson, S; Giles, F; Jabbour, E; Kantarjian, H; Karsten, V; Kornblau, S; O'Brien, S; Ravandi, F; Sznol, M; Thomas, D; Verstovsek, S; Yee, K | 1 |
| Berman, E; Bhalla, K; Copelan, EA; Devetten, MP; Emanuel, PD; Erba, HP; Greenberg, PL; Moore, JO; O'Brien, S; Przepiorka, D; Radich, JP; Schilder, RJ; Shami, P; Smith, BD; Snyder, DS; Soiffer, RJ; Tallman, MS; Talpaz, M; Wetzler, M | 1 |
| Crump, M; Keating, A; Kuruvilla, J; Nagy, T; Pintilie, M; Tsang, R | 1 |
| Druker, BJ; Guerci-Bresler, A; Guilhot, F; Guilhot, J; Krahnke, T; Larson, RA; Massimini, G; O'Brien, S; Roy, L; So, C | 1 |
| Ho, SJ; Manoharan, A | 1 |
| Braeckman, R; Chamberlain, M; Maria, B; Phuphanich, S | 1 |
| Huh, J; Jeong, YP; Kim, S; Kim, SB; Kim, SW; Ko, OB; Koo, JE; Lee, D; Lee, JL; Park, SH; Suh, C | 1 |
| Albitar, M; Day, A; Do, KA; Estey, E; Giles, FJ; Jilani, I; Johnson, M; Kantarjian, H; Keating, M; O'brien, S; Pierce, S; Verstovsek, S | 1 |
| Aisa, Y; Ikeda, Y; Kato, J; Mihara, A; Mori, T; Nakazato, T; Okamoto, S; Shimizu, T; Takayama, N; Watanabe, R; Yamazaki, R; Yokoyama, A | 1 |
| Arceci, RJ; Chen, AR; Colombani, P; Higman, MA; Schwartz, CL; Wharam, M; Williams, KM | 1 |
| Fujishima, M; Fujishima, N; Hirokawa, M; Inomata, M; Kameoka, Y; Saitoh, H; Saitoh, K; Sawada, K; Takahashi, N; Yamanaka, Y; Yoshioka, T | 1 |
| Abidi, MH; Ibrahim, RB; Maria, D; Peres, E; Tove, I | 1 |
| Ahmed, P; Akhtar, F; Akhtar, FM; Chaudhry, QU; Kamal, MK; Khan, B; Raza, S; Satti, TM; Ullah, K | 1 |
| Fukushima, M; Ichinohe, T; Ishikawa, T; Kadowaki, N; Kasai, Y; Kitawaki, T; Kondo, T; Maekawa, T; Teramukai, S; Uchiyama, T | 1 |
| Caballero, D; Canals, C; Finke, J; Goldstone, A; Hunter, A; Kienast, J; Kobbe, G; Kolb, HJ; Kyriakou, C; Metzner, B; Oberg, G; Reimer, P; Schmitz, N; Sureda, A; Theorin, N | 1 |
| Alessandrino, EP; Arcaini, L; Bernasconi, P; Bonfichi, M; Bottelli, C; Brusamolino, E; Cairoli, R; Calatroni, S; Gargantini, L; Lazzarino, M; Majolino, I; Merli, M; Montanari, F; Morra, E; Pascutto, C; Passamonti, F; Rossi, G; Troletti, D; Tucci, A; Zoli, V | 1 |
| Barbui, T; Benedetti, F; Boccadoro, M; Ciceri, F; Corradini, P; Cortelazzo, S; Gallamini, A; Gianni, AM; Magni, M; Majolino, I; Mirto, S; Passera, R; Patti, C; Pileri, A; Pizzolo, G; Rambaldi, A; Tarella, C; Zanni, M | 1 |
| Coia, LR; Goldberg, M; Keller, SM; Langer, C; Sauter, ER | 1 |
| Gunning, K; Harman, K; Mahendra, P; Marcus, RE; Phillips, M | 1 |
| Hirakawa, K; Horiike, S; Kaneko, H; Kashima, K; Misawa, S; Nakai, H; Nakao, M; Taniwaki, M; Ueda, Y | 1 |
| Grande, M | 1 |
| Dunphy, CH; Kitchen, S; Saravia, O; Velasquez, WS | 1 |
| Baldicchi, L; Corneo, GM; Mangiagalli, M; Miccolis, IR; Pioltelli, P; Pogliani, EM | 1 |
| Audouin, J; Bernadou, A; Chauvenet, L; Ciaudo, M; Favier, R; Horellou, MH; Rossert, J; Samama, M | 1 |
| Bastit, D; Boulet, D; Fruchart, C; Moncondult, M; Piguet, H; Stamatoullas, A; Tilly, H | 1 |
| Jowitt, SN; Yin, JA | 1 |
| Amabile, M; Arpinati, M; Farabegoli, P; Martinelli, G; Testoni, N; Tura, S; Visani, G; Zaccaria, A; Zinzani, PL; Zuffa, E | 1 |
| Chong, R; Goh, YT; Lee, LH; Ng, HS; Tan, P; Wong, GC | 1 |
| Appelbaum, FR; Banker, DE; Groudine, M; Norwood, T | 1 |
| Adle-Biassette, H; Authier, FJ; Chomienne, C; Defer, GL; Degos, JD; Degos, L; Martin, L; Ricolfi, F | 1 |
| Gieseler, F; Gullis, E; Nuessler, V; Pelka-Fleischer, R; Stötzer, O; Wilmanns, W; Zwierzina, H | 1 |
| Cosson, A; Fenaux, P; Grardel, N; Lepelley, P; Poulain, S; Preudhomme, C | 1 |
| Hagiwara, S; Hirano, N; Miwa, A; Takezako, N; Togawa, A; Yuo, A | 1 |
| Chalmers, EA; Clark, RE; Crotty, G; Franklin, IM; Goldstone, AH; Hepplestone, A; Kelsey, SM; McBride, N; McCann, SR; Newland, AC; Sharp, RA; Singer, IO; Sproul, AM; Tansey, PJ; Watson, W | 1 |
| Benesch, M; Kerbl, R; Lackner, H; Oberbauer, R; Pakisch, B; Schwinger, W; Urban, C | 1 |
| Biondi, A; Coppi, MR; Liso, V; Mestice, A; Mininni, D; Palumbo, G; Pogliani, EM; Rossi, V; Specchia, G; Teruzzi, E | 1 |
| Curti, A; Lemoli, RM; Leopardi, G; Motta, MR; Rizzi, S; Testoni, N; Tura, S; Visani, G | 1 |
| Mollee, PN; Rodwell, R; Taylor, D; Taylor, KM; Williams, B | 1 |
| Abgrall, JP; Brice, P; Brion, A; Caillot, D; Cordonnier, C; Desablens, B; Dreyfus, F; Fenaux, P; Gratecos, N; Guerci, A; Hecquet, B; Hoang-Ngoc, L; Ifrah, N; Janvier, M; Leporrier, M; Lioure, B; Milpied, N; Pignon, B; Rochant, H; Sadoun, A; Solary, E; Stoppa, AM; Tilly, H; Veil, A; Wattel, E | 1 |
| Buhk, T; Dörries, K; Eggers, C; Stellbrink, HJ | 1 |
| Chamberlain, MC; Cole, BF; Glantz, MJ; Howell, SB; Jaeckle, KA; LaFollette, S; Maria, B; Phuphanich, S; Recht, L; Schumann, GB; Swinnen, LJ | 1 |
| Caracciolo, D; Corradini, P; Cuttica, A; Gavarotti, P; Ladetto, M; Novero, D; Pileri, A; Rossi, G; Tarella, C; Zallio, F | 1 |
| Berglund, A; Carlson, K; Enblad, G; Glimelius, B; Hagberg, H | 1 |
| Craig, C | 1 |
| Clark, RE; Durham, BH; Flory, AJ; Fraser, WD; Ion, EM; Woodcock, BE | 1 |
| Jantunen, E; Mahlamäki, E; Nousiainen, T | 1 |
| Deininger, MH; Grote, E; Meyermann, R; Wickboldt, J | 1 |
| Bouafia, F; Coiffier, B; Dumontet, C; Espinouse, D; Hequet, O; Salles, G; Thieblemont, C | 1 |
| Aranoff, GS; Feldstein, NA; Garvin, JH; Hays, AP; Levine, LS; Oberfield, SE; Silfen, ME; Starkman, HS; Wong, B | 1 |
| Guenther, PP; Huebner, A; Neumeister, V; Parwaresch, R; Sobottka, SB; Todt, H; Weissbach, G | 1 |
| Abdulkadyrov, KM; Kornilova, TA; Martynkevich, IS; Rukavitsyn, OA; Udal'eva, VI | 1 |
| Aoki, N; Beck, JR; Giles, FJ; Guilhot, F; Guilhot, J; Wirt, DP | 1 |
| Ahmed, T; Feldman, EJ; Kancherla, R; Liu, D; Papageorgio, C; Pozzuoli, M; Seiter, K; Sreekantaiah, C; Weisberger, J; Weiss, M | 1 |
| Abe, T; Arai, Y; Gotoh, S; Ishikawa, T; Kakazu, N; Matsushita, A; Nagai, K; Ohki, M; Ohno, T; Shinzato, I; Takahashi, T; Tsuchiya, T | 1 |
| Aoki, S; Imai, K; Kazama, Y; Shimizu, H; Takahashi, T; Tsujisaki, M; Yoshimoto, M | 1 |
| Cobos, E; Keung, YK; Morgan, D | 1 |
| Berger, F; Brice, P; Colin, P; Diviné, M; Fermé, C; Jaubert, J; Lederlin, P; Mounier, N; Reman, O; Salles, G; Stamatoullas, A; Voillat, L | 1 |
| Iwakiri, R; Kumakawa, T; Mikoshiba, M; Mori, M; Ohta, M; Tsutsumi, H | 1 |
| Hara, T; Hattori, H; Ishii, S; Matsuzaki, A; Suminoe, A | 1 |
| Alimena, G; Breccia, M; Carmosino, I; D'Andrea, M; D'Elia, GM; Petti, MC | 1 |
| Gerrard, M; Hobson, R; Imeson, J; McCarthy, K; Pinkerton, CR; Williams, DM | 1 |
13 review(s) available for cytarabine and Disease Exacerbation
| Article | Year |
|---|---|
Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytarabine; Dacarbazine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Glioma; Humans; Hydroxyurea; Lomustine; Methylprednisolone; Middle Aged; Neoplasm Recurrence, Local; Procarbazine; Randomized Controlled Trials as Topic; Temozolomide; Vincristine | 2017 |
[Myelodysplastic syndromes: treatment strategy up-to-date].
Topics: Antilymphocyte Serum; Azacitidine; Benzoates; Cyclosporine; Cytarabine; Deferasirox; Disease Progression; Drug Discovery; Drug Therapy, Combination; Erythropoietin; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life; Risk Assessment; Thalidomide; Triazoles | 2014 |
Hyperleukocytotic secondary acute myeloid leukemia (AML) with sole monosomy 7 as sequela of Philadelphia-chromosome positive chronic myeloid leukemia (CML).
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 7; Cytarabine; Disease Progression; Fatal Outcome; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Leukocytosis; Male; Monosomy; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Selection, Genetic | 2009 |
[Plasmacytoid dendritic cell tumor].
Topics: Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Dendritic Cells; Disease Progression; Doxorubicin; Humans; Immunophenotyping; Leukemia, Myelomonocytic, Acute; Lymph Nodes; Lymphoma, Non-Hodgkin; Male; Mercaptopurine; Methotrexate; Middle Aged; Prednisone; Prognosis; Remission Induction; Skin Neoplasms; Transplantation, Homologous; Vincristine | 2011 |
Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Aberrations; Cytarabine; Disease Progression; Drug Evaluation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Outcome Assessment, Health Care; Quality of Life; Risk Assessment; Sickness Impact Profile | 2012 |
Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Cranial Irradiation; Cytarabine; Dementia; Dementia, Vascular; Demyelinating Diseases; Disease Progression; Doxorubicin; Epilepsy, Complex Partial; Etoposide; Eye Neoplasms; Fatal Outcome; Female; Gait Disorders, Neurologic; Humans; Immunocompetence; Intracranial Arteriosclerosis; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Procarbazine; Radiation Injuries; Retrospective Studies; Survival Analysis; Thiotepa; Vincristine | 2004 |
Granulocytic sarcoma of the testis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Nucleolus; Chemotherapy, Adjuvant; Chromatin; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease Progression; Humans; Leukemia, Myeloid, Acute; Male; Methotrexate; Orchiectomy; Radiotherapy, Adjuvant; Sarcoma, Myeloid; Testicular Neoplasms | 2004 |
Treatment intensity significantly influencing fibrosis in bone marrow independently of the cytogenetic response: meta-analysis of the long-term results from two prospective controlled trials on chronic myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Chromosome Aberrations; Controlled Clinical Trials as Topic; Cytarabine; Cytogenetic Analysis; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Primary Myelofibrosis; Prospective Studies; Risk Factors; Survival Rate | 2004 |
Outcome of elderly patients with aggressive Non-Hodgkin's lymphoma refractory to or relapsing after first-line CHOP or CHOP-like chemotherapy: a low probability of cure.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Drug Evaluation; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Life Tables; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Vincristine | 2004 |
Acute myelofibrosis terminating in acute lymphoblastic leukemia: case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blast Crisis; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Daunorubicin; Disease Progression; Flow Cytometry; Humans; Immunophenotyping; Male; Mercaptopurine; Methotrexate; Neoplastic Stem Cells; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Primary Myelofibrosis; Remission Induction; Vincristine | 1996 |
Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 11; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytarabine; Disease Progression; Disease-Free Survival; Enzyme Inhibitors; Etoposide; Female; Humans; Idarubicin; Incidence; Karyotyping; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Neoplasm Proteins; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Topoisomerase II Inhibitors; Treatment Outcome; Tretinoin | 2001 |
Unrelated cord blood transplantation for an infant with chemotherapy-resistant progressive Langerhans cell histiocytosis.
Topics: Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Drug Resistance; Drug Therapy, Combination; Etoposide; Fetal Blood; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histiocytosis, Langerhans-Cell; Humans; Infant; Male; Mercaptopurine; Methotrexate; Methylprednisolone; Mitoxantrone; Prednisolone; Remission Induction; Transplantation Conditioning; Transplantation, Homologous; Vincristine | 2001 |
Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom Children's Cancer Study Group chemotherapy regimens.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Disease Progression; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Infant; Lymphoma, Large-Cell, Anaplastic; Male; Methotrexate; Prednisolone; Recurrence; Risk; Thioguanine; United Kingdom; Vincristine | 2002 |
36 trial(s) available for cytarabine and Disease Exacerbation
| Article | Year |
|---|---|
Immunohistochemistry for c-myc and bcl-2 overexpression improves risk stratification in primary central nervous system lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Central Nervous System Neoplasms; Cytarabine; Disease Progression; Female; Follow-Up Studies; Humans; Immunohistochemistry; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Retrospective Studies; Risk Assessment; Survival Rate | 2020 |
Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study.
Topics: Cytarabine; Disease Progression; Down Syndrome; Historically Controlled Study; Humans; Infant; Infant, Newborn; Leukemia, Myeloid; Leukemoid Reaction; Neoplasm, Residual; Survival Analysis | 2018 |
Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Recurrence; Rituximab; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2013 |
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Disease Progression; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Targeted Therapy; Piperazines; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Risk Factors; Time Factors; Treatment Outcome; Young Adult | 2014 |
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Topics: Adult; Age Factors; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cytarabine; Daunorubicin; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Germany; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Recurrence; Risk Factors; Sorafenib; Time Factors; Transplantation, Homologous; Treatment Outcome | 2015 |
Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cytarabine; Disease Progression; Drug Resistance, Neoplasm; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Middle Aged; Prednisone; Recurrence; Retreatment; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Young Adult | 2016 |
Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cytarabine; Disease Progression; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoadjuvant Therapy; Treatment Outcome; Young Adult | 2009 |
CHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Progression; Doxorubicin; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Radiotherapy Dosage; Remission Induction; Vincristine | 2011 |
Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Cytarabine; Disease Progression; Down Syndrome; Female; Follow-Up Studies; Humans; Infant; Infant, Newborn; Kaplan-Meier Estimate; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid; Male; Myeloproliferative Disorders; Prognosis; Prospective Studies; Time Factors; Treatment Outcome | 2011 |
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Cytogenetic Analysis; Disease Progression; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Remission Induction; Survival Rate; Young Adult | 2012 |
Fludarabine with cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with poor-risk chronic lymphocytic leukemia.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prospective Studies; Recurrence; Risk; Rituximab; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Vincristine; Whole-Body Irradiation | 2013 |
An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Cytarabine; Delayed-Action Preparations; Disease Progression; Female; Humans; Injections, Spinal; Male; Meningeal Neoplasms; Middle Aged; Survival Analysis | 2002 |
Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion.
Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Blood Donors; Carmustine; Cytarabine; Disease Progression; Etoposide; Female; Graft Survival; Graft vs Host Disease; Humans; Immunosuppression Therapy; Lymphocyte Transfusion; Lymphoproliferative Disorders; Male; Melphalan; Middle Aged; Monitoring, Physiologic; Secondary Prevention; Stem Cell Transplantation; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2001 |
Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dexamethasone; Disease Progression; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Survival Analysis; Time Factors; Vidarabine | 2002 |
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Disease Progression; Female; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Prospective Studies; Pyrimidines; Survival Rate | 2003 |
Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Cytogenetic Analysis; Disease Progression; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Remission Induction; Treatment Outcome | 2003 |
Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis.
Topics: Adult; Cytarabine; Delayed-Action Preparations; Disease Progression; Humans; Injections, Spinal; Meningeal Neoplasms; Meningitis; Methotrexate; Neoplasms; Quality of Life; Survival Analysis | 2003 |
A pilot study of CODOX-M/IVAC in primary refractory or relapsed high-grade non-Hodgkin's lymphoma. A Scotland and Newcastle Lymphoma Group Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Ifosfamide; Injections, Spinal; Lenograstim; Leucovorin; Lymphoma, Non-Hodgkin; Male; Mesna; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Pilot Projects; Prognosis; Recombinant Proteins; Salvage Therapy; Sepsis; Treatment Outcome; Vincristine | 2003 |
[Imatinib-New, molecular therapeutic possibility in chronic myeloid leukemia. The IRIS Study].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Disease Progression; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Treatment Outcome | 2004 |
Results of autologous transplantation in lymphoma are not improved by increasing the dose of etoposide in the BEAM regimen: a single-centre sequential-cohort study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort Studies; Cytarabine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma; Male; Melphalan; Middle Aged; Multivariate Analysis; Retrospective Studies; Time Factors; Transplantation Conditioning; Transplantation, Autologous | 2004 |
Outcome of children with B cell lymphoma in Venezuela with the LMB-89 protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Cytarabine; Disease Progression; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hepatitis B; Hepatitis B Vaccines; Humans; Hydrocortisone; Leucovorin; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Methotrexate; Prednisone; Recurrence; Treatment Outcome; Venezuela; Vincristine | 2004 |
Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Progression; Disease-Free Survival; Doxorubicin; Etoposide; Follow-Up Studies; Humans; Life Tables; Lymphoma, Mantle-Cell; Peripheral Blood Stem Cell Transplantation; Prednisone; Prognosis; Prospective Studies; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Vincristine; Whole-Body Irradiation | 2004 |
Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia.
Topics: Adult; Aged; Alkylating Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Base Pair Mismatch; Cohort Studies; Cytarabine; Disease Progression; DNA; DNA Repair; Female; Humans; Hydrazines; Leukemia; Leukocytes, Mononuclear; Male; Middle Aged; Models, Chemical; O(6)-Methylguanine-DNA Methyltransferase; Sulfonamides; Time Factors | 2005 |
A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Cytarabine; Delayed-Action Preparations; Disease Progression; Female; Humans; Injections, Spinal; Leukemia; Lymphoma; Male; Meningeal Neoplasms; Meningitis; Middle Aged | 2007 |
ESHAP salvage therapy for refractory and relapsed non-Hodgkin's lymphoma: a single center experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Disease Progression; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Neoplasm Recurrence, Local; Prednisone; Salvage Therapy; Survival Analysis; Treatment Failure | 2006 |
Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma.
Topics: Adult; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Purging; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Genes, bcl-2; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Immunologic Factors; Immunosuppressive Agents; Kaplan-Meier Estimate; Lymphoma, Follicular; Male; Middle Aged; Multivariate Analysis; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Rituximab; Time Factors; Transplantation, Autologous; Treatment Outcome; Vincristine | 2008 |
Optimal management of malignant mesothelioma after subtotal pleurectomy: revisiting the role of intrapleural chemotherapy and postoperative radiation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cytarabine; Disease Progression; Drug Administration Schedule; Female; Humans; Male; Mesothelioma; Middle Aged; Mitomycin; Pleura; Pleural Neoplasms; Postoperative Care; Radiotherapy, Adjuvant; Survival Analysis; Thoracotomy | 1995 |
Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Disease Progression; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Life Tables; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Recombinant Proteins; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome; Whole-Body Irradiation | 1996 |
All-trans retinoic acid in relapsing malignant gliomas: clinical and radiological stabilization associated with the appearance of intratumoral calcifications.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Calcinosis; Cytarabine; Disease Progression; Female; Glioblastoma; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Radiography; Time Factors; Tretinoin | 1997 |
Expression of lung resistance protein and correlation with other drug resistance proteins and outcome in myelodysplastic syndromes.
Topics: Acute Disease; Antibiotics, Antineoplastic; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytarabine; Danazol; Disease Progression; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation; Hematopoietic Stem Cells; Humans; Karyotyping; Leukemia, Myeloid; Leukemia, Myelomonocytic, Chronic; Life Tables; Myelodysplastic Syndromes; Neoplasm Proteins; Proto-Oncogene Proteins c-bcl-2; Quinine; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53; Vault Ribonucleoprotein Particles | 1998 |
Autologous transplantation in chronic myeloid leukaemia using peripheral blood stem cells.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytarabine; Disease Progression; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Survival Analysis; Transplantation, Autologous; Treatment Outcome | 1998 |
Synchronous radiochemotherapy in unfavorable brain tumors of children and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Deafness; Disease Progression; Disease-Free Survival; Etoposide; Follow-Up Studies; Glioma; Hearing Loss; Hematologic Diseases; Humans; Ifosfamide; Infections; Life Tables; Lomustine; Medulloblastoma; Methotrexate; Prognosis; Radiotherapy, Adjuvant; Remission Induction; Vincristine | 1998 |
Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Français des Myélodysplasies (GFM) and Groupe GOELAMS.
Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Aberrations; Cytarabine; Disease Progression; Female; Genes, MDR; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Phenotype; Quinine; Remission Induction; Survival Analysis | 1999 |
A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cytarabine; Delayed-Action Preparations; Disease Progression; Female; Humans; Injections, Spinal; Lung Neoplasms; Male; Melanoma; Meningeal Neoplasms; Methotrexate; Middle Aged; Neoplasms; Prospective Studies; Survival Rate; Survivors | 1999 |
A prospective study of intensive induction therapy with high-dose consolidation in patients with aggressive non-Hodgkin's lymphoma and two or three adverse prognostic factors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Feasibility Studies; Female; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Prognosis; Prospective Studies; Treatment Outcome | 2000 |
Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Male; Melphalan; Middle Aged; Mitoguazone; Recurrence; Salvage Therapy; Transplantation, Autologous; Vinblastine; Vinorelbine | 2002 |
111 other study(ies) available for cytarabine and Disease Exacerbation
| Article | Year |
|---|---|
TSTA3 facilitates esophageal squamous cell carcinoma progression through regulating fucosylation of LAMP2 and ERBB2.
Topics: Aged; Animals; Carbohydrate Epimerases; Cell Line, Tumor; Cell Proliferation; Disease Progression; DNA Copy Number Variations; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagus; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glycosylation; Guanosine Diphosphate Fucose; Humans; Ketone Oxidoreductases; Lysosomal-Associated Membrane Protein 2; Male; Mice; Middle Aged; Prognosis; Receptor, ErbB-2; Whole Genome Sequencing; Xenograft Model Antitumor Assays | 2020 |
Detection of residual and chemoresistant leukemic cells in an immune-competent mouse model of acute myeloid leukemia: Potential for unravelling their interactions with immunity.
Topics: Animals; Cytarabine; Disease Models, Animal; Disease Progression; Humans; Leukemia, Myeloid, Acute; Mice; Neoplasm, Residual | 2022 |
Platelet-derived microparticles provoke chronic lymphocytic leukemia malignancy through metabolic reprogramming.
Topics: Antineoplastic Agents; Cell-Derived Microparticles; Cytarabine; Disease Progression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell | 2023 |
Results of R-ESHAP as salvage therapy in refractory/relapsed follicular lymphoma: a real-world experience on behalf of GELCAB group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Disease Progression; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Lymphoma, Follicular; Male; Methylprednisolone; Middle Aged; Neoplasm Grading; Recurrence; Retrospective Studies; Rituximab; Salvage Therapy; Spain; Survival Analysis; Treatment Failure; Treatment Outcome; Young Adult | 2020 |
Double remission of chronic lymphocytic leukemia and secondary acute myeloid leukemia after venetoclax monotherapy: A case report.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Leukocyte Count; Lymphocyte Count; Male; Middle Aged; Remission Induction; Sulfonamides; Treatment Outcome | 2021 |
Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Disease Progression; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Outcome Assessment, Health Care; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Recurrence; Retrospective Studies; Rituximab; State Medicine; United Kingdom; Withholding Treatment | 2021 |
Progressive mantle cell lymphoma presenting with intractable pruritus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dexamethasone; Disease Progression; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Oxaliplatin; Pruritus; Rituximab | 2021 |
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Cyclosporine; Cytarabine; Decitabine; Disease Progression; Enzyme Inhibitors; Erythrocyte Transfusion; Female; Hematinics; Humans; Hydroxyurea; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide; Treatment Failure; Tretinoin; Valproic Acid | 2017 |
Escalated anthracycline dose in adult AML.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Cytarabine; Disease Progression; Disease-Free Survival; Etoposide; Humans; Idarubicin; Leukemia, Myeloid, Acute; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome | 2017 |
A life-threatening ruxolitinib discontinuation syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Diagnosis, Differential; Disease Progression; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Janus Kinase 2; Leukemia, Myeloid, Acute; Middle Aged; Nitriles; Pneumonia; Protein Kinase Inhibitors; Pulmonary Embolism; Pyrazoles; Pyrimidines; Remission Induction; Respiratory Distress Syndrome; Substance Withdrawal Syndrome; Thrombocythemia, Essential; Tomography, X-Ray Computed | 2017 |
Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Child; Cytarabine; Dexamethasone; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Lymphoma; Male; Methotrexate; Middle Aged; Proportional Hazards Models; Remission Induction; Rituximab; Survival Analysis; Treatment Outcome; Young Adult | 2017 |
Adult Langerhans cell histiocytosis with pulmonary and colorectoanal involvement: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Anus Diseases; Colonic Diseases; Colonoscopy; Cytarabine; Disease Progression; Histiocytosis, Langerhans-Cell; Humans; Lung Diseases; Male; Prednisone; Rectal Diseases; Tomography, X-Ray Computed; Vinblastine | 2017 |
Clinical resistance associated with a novel MAP2K1 mutation in a patient with Langerhans cell histiocytosis.
Topics: Adolescent; Adrenal Cortex Hormones; Butadienes; Combined Modality Therapy; Cytarabine; Disease Progression; Drug Resistance; Drug Therapy, Combination; Enzyme Activation; Exons; HEK293 Cells; Hematopoietic Stem Cell Transplantation; Histiocytosis, Langerhans-Cell; Humans; Male; MAP Kinase Kinase 1; MAP Kinase Signaling System; Molecular Targeted Therapy; Mutation; Nitriles; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrazoles; Pyridones; Pyrimidinones; Recombinant Fusion Proteins; Sequence Deletion; Thiophenes; Vincristine | 2018 |
Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Cytarabine; Disease Progression; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Risk Factors; Survival Rate | 2019 |
In-silico comparison of two induction regimens (7 + 3 vs 7 + 3 plus additional bone marrow evaluation) in acute myeloid leukemia treatment.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Proliferation; Computer Simulation; Cytarabine; Disease Progression; Humans; Leukemia, Myeloid, Acute; Systems Biology; Time Factors | 2019 |
A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease Progression; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Induction Chemotherapy; International Cooperation; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Remission Induction; Retrospective Studies; Transplantation Conditioning; Treatment Outcome | 2019 |
Systemic and prophylactic intrathecal chemotherapy for primary adrenal lymphoma: A retrospective study of 20 case reports.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dexamethasone; Disease Progression; Drug Administration Schedule; Drug Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Injections, Spinal; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Mortality; Retrospective Studies; Survival Analysis; Transplantation, Autologous; Treatment Outcome | 2019 |
Seven-year follow-up of allogeneic transplant using BCNU, etoposide, cytarabine and melphalan chemotherapy in patients with Hodgkin lymphoma after autograft failure: importance of minimal residual disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease Progression; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Neoplasm Recurrence, Local; Neoplasm, Residual; Prognosis; Transplantation, Autologous; Transplantation, Homologous; Treatment Failure; Treatment Outcome | 2014 |
Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biopsy; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cytarabine; Disease Progression; Female; Fibronectins; HL-60 Cells; Humans; Interleukin-2; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Mice, SCID; Middle Aged; Neoplasm Transplantation; Neovascularization, Pathologic; Young Adult | 2013 |
Neurological and cytological response as potential early predictors of time-to-progression and overall survival in patients with leptomeningeal carcinomatosis treated with intrathecal liposomal cytarabine: a retrospective cohort study.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Cytarabine; Cytodiagnosis; Disease Progression; Female; Follow-Up Studies; Humans; Injections, Spinal; Liposomes; Male; Meningeal Carcinomatosis; Middle Aged; Neoplasm Staging; Neoplasms; Nervous System Diseases; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Young Adult | 2013 |
[Exudative pericardial effusion and oligoarthritis in a patient newly diagnosed with myelodysplastic syndrome].
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Arthritis; Azacitidine; Cytarabine; Disease Progression; Etoposide; Fatal Outcome; Hepatomegaly; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Pericardial Effusion; Pleural Effusion; Serositis | 2014 |
Langerhans cell sarcoma of the nasopharynx: a rare case.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cladribine; Cytarabine; Disease Progression; Etoposide; Fatal Outcome; Humans; Langerhans Cell Sarcoma; Male; Nasopharyngeal Neoplasms; Prednisone | 2013 |
Laryngeal chloroma heralding relapse of acute myeloid leukemia.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Cytarabine; Disease Progression; Dose Fractionation, Radiation; Fatal Outcome; Humans; Laryngeal Neoplasms; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Respiratory Insufficiency; Sarcoma, Myeloid; Stem Cell Transplantation; Tomography, X-Ray Computed | 2014 |
Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Case-Control Studies; Chemotherapy, Adjuvant; Cladribine; Cytarabine; Disease Progression; Drug Resistance, Neoplasm; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Recombinant Proteins; Treatment Failure; Young Adult | 2014 |
Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Consolidation Chemotherapy; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Etoposide; Female; Humans; Induction Chemotherapy; Lymphoma, B-Cell; Male; Melphalan; Methylprednisolone; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Podophyllotoxin; Prednisone; Prognosis; Rituximab; Treatment Outcome; Vincristine; Young Adult | 2015 |
Positron emission tomography/computed tomography findings during therapy predict outcome in patients with diffuse large B-cell lymphoma treated with chemotherapy alone but not in those who receive consolidation radiation.
Topics: Age Factors; Aged; Analysis of Variance; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Progression; Doxorubicin; Drug Administration Schedule; Female; Fluorodeoxyglucose F18; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Positron-Emission Tomography; Prednisone; Prognosis; Radiopharmaceuticals; Remission Induction; Retrospective Studies; Rituximab; Sex Factors; Time Factors; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome; Vincristine | 2014 |
Progressive multifocal leukoencephalopathy complicating untreated chronic lymphatic leukemia: case report and review of the literature.
Topics: Cytarabine; Disease Progression; Female; Humans; JC Virus; Leukemia, Lymphocytic, Chronic, B-Cell; Leukoencephalopathy, Progressive Multifocal; Mefloquine; Mianserin; Middle Aged; Mirtazapine; Treatment Failure | 2014 |
Temporal dynamics of hippocampal neurogenesis in chronic neurodegeneration.
Topics: Adult; Aged; Alzheimer Disease; Animals; Antimetabolites, Antineoplastic; Cell Proliferation; Chronic Disease; Creutzfeldt-Jakob Syndrome; Cytarabine; Dentate Gyrus; Disease Models, Animal; Disease Progression; Female; Genetic Vectors; Hippocampus; Humans; Male; Mice; Mice, Inbred C57BL; Middle Aged; Mossy Fibers, Hippocampal; Neural Pathways; Neural Stem Cells; Neuroanatomical Tract-Tracing Techniques; Neurodegenerative Diseases; Neurogenesis; Patch-Clamp Techniques; Prion Diseases; Prions; Time Factors; Tissue Banks; Young Adult | 2014 |
Optic nerve involvement of Waldenström's macroglobulinemia: with autopsy findings.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autopsy; Blindness; Cytarabine; Disease Progression; Fatal Outcome; Humans; Lymphocytes; Magnetic Resonance Imaging; Male; Methotrexate; Optic Nerve; Prednisolone; Waldenstrom Macroglobulinemia | 2014 |
[Neoplastic mastocytosis evolving from a poor prognosis acute myeloid leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease Progression; Drug Resistance, Neoplasm; Fatal Outcome; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunophenotyping; Leukemia, Mast-Cell; Leukemia, Myeloid, Acute; Mast Cells; Mutation; Neoplasm Proteins; Neoplastic Stem Cells; Prognosis; Vidarabine | 2015 |
Variegated clonality and rapid emergence of new molecular lesions in xenografts of acute lymphoblastic leukemia are associated with drug resistance.
Topics: Animals; Antineoplastic Agents; Biopsy; Clone Cells; Cytarabine; Deoxycytidine Kinase; Dexamethasone; Disease Progression; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Gene Dosage; Heterografts; Humans; Male; Methotrexate; Mice; Mice, Inbred NOD; Mice, SCID; Mutation; Neoplasm Proteins; Neoplasm Transplantation; Neoplastic Stem Cells; Peptide Synthases; Polymorphism, Single Nucleotide; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Radiation Chimera; Sequence Analysis, DNA; Vincristine | 2015 |
High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease Progression; Etoposide; Female; France; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Prognosis; Recurrence; Retrospective Studies; Survival Analysis; Transplantation, Autologous; Treatment Outcome | 2015 |
Cerebral involvement as the first extracutaneous manifestation of mycosis fungoides.
Topics: Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Brain; Carmustine; Combined Modality Therapy; Cytarabine; Disease Progression; Fatal Outcome; Female; Humans; Lymphoma, Large-Cell, Anaplastic; Memory Disorders; Methotrexate; Middle Aged; Mycosis Fungoides; Nystagmus, Pathologic; PUVA Therapy; Skin Neoplasms; Tetrahydronaphthalenes | 2015 |
Analysis of Japanese Patients Treated with or without Long-Term Epirubicin Plus Ara-C Intravesical Instillation Therapy for Low-Grade Superficial Bladder Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease Progression; Epirubicin; Female; Follow-Up Studies; Humans; Japan; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Treatment Outcome; Urinary Bladder Neoplasms | 2015 |
Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Cytarabine; Decitabine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Recurrence; Remission Induction; Treatment Outcome | 2016 |
Treatment of diffuse large B-cell lymphoma with secondary central nervous system involvement: encouraging efficacy using CNS-penetrating R-IDARAM chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cytarabine; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Humans; Idarubicin; Infusions, Intravenous; Injections, Spinal; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Retrospective Studies; Rituximab; Treatment Outcome | 2016 |
Cytomegalovirus Pneumonia after Anti-CC-chemokine Receptor 4 Monoclonal Antibody (Mogamulizumab) Therapy in an Angioimmunoblastic T-cell Lymphoma Patient.
Topics: Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cisplatin; Cyclophosphamide; Cytarabine; Cytomegalovirus Infections; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fatal Outcome; Humans; Immunoblastic Lymphadenopathy; Lymphoma, T-Cell; Male; Methylprednisolone; Middle Aged; Pneumonia, Viral; Prednisone; Receptors, CCR4; Vincristine | 2016 |
A 5-day cytoreductive chemotherapy followed by haplo-identical hsct (FA5-BUCY) as a tumor-ablative regimen improved the survival of patients with advanced hematological malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chemotherapy, Adjuvant; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infant; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Proportional Hazards Models; Recurrence; Remission Induction; Time Factors; Transplantation Conditioning; Transplantation, Haploidentical; Treatment Outcome; Vidarabine; Young Adult | 2016 |
Clofarabine-based consolidation therapy in AML.
Topics: Adenine Nucleotides; Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Consolidation Chemotherapy; Cytarabine; Disease Progression; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Young Adult | 2017 |
Infiltration of the spinal cord in a patient with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Dexamethasone; Disease Progression; Fatal Outcome; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Neoplasm Metastasis; Pyrazines; Spinal Cord Neoplasms | 2008 |
Sequential salvage chemotherapy for recurrent intracranial hemangiopericytoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Cyclophosphamide; Cytarabine; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Routes; Drug Administration Schedule; Etoposide; Female; Hemangiopericytoma; Humans; Ifosfamide; Interferon-alpha; Kaplan-Meier Estimate; Liposomes; Magnetic Resonance Spectroscopy; Male; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Rare Diseases; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Vincristine | 2008 |
[Granulocytic sarcoma of the prostate presenting with urinary obstruction which progressed to acute myeloid leukemia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease Progression; Dysuria; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Neoplasms, Second Primary; Prostatic Neoplasms; Remission Induction; Sarcoma, Myeloid | 2008 |
Influence of the stage of advancement of leukemia L1210 in mice on the optimal schedule of treatment of cytosine arabinoside (NSC-63878).
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Cell Proliferation; Cyclophosphamide; Cytarabine; Disease Progression; Drug Administration Schedule; Injections, Intraperitoneal; Leukemia L1210; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Neoplasm Transplantation; Time Factors | 1972 |
[Prophylaxis and treatment of modified BFM-90 regimen for lymphoblastic lymphoma in children and adolescents accompanied with infection].
Topics: Adolescent; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bacterial Infections; Cephalosporins; Child; Child, Preschool; Cross Infection; Cyclophosphamide; Cytarabine; Daunorubicin; Disease Progression; Female; Humans; Itraconazole; Male; Mercaptopurine; Methotrexate; Mouth Diseases; Mycoses; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Recurrence; Remission Induction; Respiratory Tract Infections; Vincristine | 2009 |
[Therapeutic management of central nervous system lymphomas in a single hematological institute].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Cranial Irradiation; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Progression; Doxorubicin; Drug Administration Schedule; Epidural Space; Female; Humans; Hungary; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prednisone; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Rituximab; Salvage Therapy; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome; Vincristine | 2009 |
Retrospective analysis of risk factors for development of liver dysfunction in transient leukemia of Down syndrome.
Topics: Cytarabine; Disease Progression; Down Syndrome; Female; Hepatomegaly; Humans; Hyaluronic Acid; Immunosuppressive Agents; Infant; Infant, Newborn; Leukemia; Liver Cirrhosis; Liver Diseases; Male; Respiration Disorders; Retrospective Studies; Risk Factors; Splenomegaly | 2011 |
Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Humans; Ifosfamide; Kaplan-Meier Estimate; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Treatment Outcome; Vincristine; Vindesine | 2011 |
Pilot study on combination of azacitidine and low-dose cytarabine for patients with refractory anemia with excess blast.
Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Disease Progression; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Pilot Projects; Treatment Outcome | 2012 |
Chemotherapy-related magnetic resonance imaging abnormalities mimicking disease progression following intraventricular liposomal cytarabine and high dose methotrexate for neurolymphomatosis.
Topics: Aged; Antineoplastic Agents; Autopsy; Brain; Brain Injuries; Chlorambucil; Cytarabine; Disease Progression; Fatal Outcome; Humans; Injections, Spinal; Leukemia, Lymphocytic, Chronic, B-Cell; Magnetic Resonance Imaging; Male; Methotrexate; Nervous System Diseases; Positron-Emission Tomography; Recurrence; Waldenstrom Macroglobulinemia | 2012 |
Acute megakaryoblastic leukemia and severe pulmonary fibrosis in a child with Down syndrome: successful treatment with ultra low-dose cytarabine using GATA1 mutation to monitor minimal residual disease.
Topics: Antimetabolites, Antineoplastic; Biomarkers; Biomarkers, Tumor; Cytarabine; Cytokines; Disease Progression; Down Syndrome; Drug Monitoring; Female; GATA1 Transcription Factor; Genetic Predisposition to Disease; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Leukemia, Megakaryoblastic, Acute; Mucin-1; Myeloproliferative Disorders; Neoplasm Proteins; Prednisone; Pulmonary Fibrosis; Remission Induction | 2012 |
Ablation of proliferating cells in the CNS exacerbates motor neuron disease caused by mutant superoxide dismutase.
Topics: Amyotrophic Lateral Sclerosis; Animals; Cell Proliferation; Cytarabine; Disease Models, Animal; Disease Progression; Humans; Insulin-Like Growth Factor I; Interleukin-6; Mice; Mice, Transgenic; Microglia; Motor Neuron Disease; Superoxide Dismutase; Transforming Growth Factor beta | 2012 |
Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: a retrospective case series.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Cytarabine; Disease Progression; Female; Follow-Up Studies; Humans; Injections, Spinal; Liposomes; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Middle Aged; Neoplasm Staging; Neoplasms; Neurotoxicity Syndromes; Prognosis; Prospective Studies; Retrospective Studies | 2012 |
Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cohort Studies; Cytarabine; Disease Progression; Drug Resistance, Neoplasm; Europe; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hodgkin Disease; Humans; Immunosuppressive Agents; Life Tables; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Proportional Hazards Models; Salvage Therapy; Survival Analysis; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML.
Topics: Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Cytarabine; Daunorubicin; Disease Progression; Drug Resistance, Neoplasm; Enzyme Inhibitors; Exons; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Recurrence; Remission Induction; Salvage Therapy | 2003 |
Combined-modality treatment of leptomeningeal gliomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Cohort Studies; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Disease Progression; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Meningeal Neoplasms; Methotrexate; Middle Aged; Radiotherapy, Adjuvant; Survival Rate; Treatment Outcome; Triethylenephosphoramide | 2003 |
Posterior leukoencephalopathy following intrathecal chemotherapy with MRA-documented vasospasm.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Blindness; Brain Diseases; Cerebral Arteries; Cerebral Infarction; Cytarabine; Disease Progression; Female; Humans; Injections, Spinal; Magnetic Resonance Angiography; Magnetic Resonance Imaging; Methotrexate; Middle Aged; Ocular Motility Disorders; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recovery of Function; Syndrome; Tachycardia; Vasospasm, Intracranial | 2003 |
Primary mediastinal large B-cell lymphoma with sclerosis in pediatric and adolescent patients: treatment and results from three therapeutic studies of the Berlin-Frankfurt-Münster Group.
Topics: Adolescent; Adrenal Cortex Hormones; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Child; Child, Preschool; Cytarabine; Disease Progression; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Infant; L-Lactate Dehydrogenase; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Prognosis; Sclerosis; Treatment Outcome | 2003 |
A case of leukemia of the appendix presenting as acute appendicitis.
Topics: Aged; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Appendectomy; Appendicitis; Appendix; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease Progression; Fatal Outcome; Humans; Idarubicin; Immunophenotyping; Leukemia, Myeloid, Acute; Leukemic Infiltration; Male; Mercaptopurine; Sarcoma, Myeloid | 2003 |
Safety of rituximab therapy during the first trimester of pregnancy: a case history.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cladribine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Progression; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Infant, Newborn; Lymphoma, Follicular; Male; Methotrexate; Mitoguazone; Peripheral Blood Stem Cell Transplantation; Prednisone; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pregnancy Trimester, First; Remission Induction; Rituximab; Safety; Transplantation, Autologous; Vincristine | 2004 |
Differentiating agents + low-dose chemotherapy in the management of old/poor prognosis patients with acute myeloid leukemia or myelodysplastic syndrome.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Cytarabine; Disease Progression; Female; Humans; Isotretinoin; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Thioguanine | 2004 |
Prolonged fever of unknown origin and hemophagocytosis evolving into acute lymphoblastic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosome Aberrations; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Fever of Unknown Origin; Histiocytosis, Non-Langerhans-Cell; Humans; Karyotyping; Male; Methotrexate; Middle Aged; Pancytopenia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Rituximab; Splenomegaly; Vincristine | 2004 |
Intraventricular cytarabine in a case of idiopathic hypertrophic pachymeningitis.
Topics: Adult; Chronic Disease; Cytarabine; Disease Progression; Dura Mater; Headache; Humans; Hypertrophy; Immunosuppressive Agents; Inflammation; Injections, Intraventricular; Male; Meningitis; Treatment Outcome | 2004 |
High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt's lymphoma in adults.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Drug Administration Schedule; Female; Humans; Leucovorin; Male; Methotrexate; Middle Aged; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Vincristine | 2004 |
The effects of IL-2, IL-6 and IL-10 levels on prognosis in patients with aggressive Non-Hodgkin's Lymphoma (NHL).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Disease Progression; Disease-Free Survival; Doxorubicin; Enzyme-Linked Immunosorbent Assay; Etoposide; Female; Follow-Up Studies; Humans; Interleukin-10; Interleukin-2; Interleukin-6; Lymphoma; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Prednisone; Prognosis; Regression Analysis; Time Factors; Treatment Outcome; Vincristine | 2004 |
ESHAP for primary cutaneous T-cell lymphomas: efficacy and tolerance in 11 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Cisplatin; Cytarabine; Disease Progression; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, T-Cell, Cutaneous; Male; Methylprednisolone; Middle Aged; Retrospective Studies; Skin Neoplasms; Time Factors; Treatment Outcome | 2005 |
Veno-occlusive disease of the liver associated with chronic myelomonocytic leukemia treated with vincristine and standard doses of cytarabine.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease Progression; Fatal Outcome; Hepatic Veno-Occlusive Disease; Humans; Hypoalbuminemia; Leukemia, Myelomonocytic, Chronic; Male; Paresis; Renal Insufficiency; Thrombocytopenia; Vincristine | 2005 |
Acute myeloid leukemia with near-triploid karyotype and extramedullary involvement of mediastinum.
Topics: Adult; Antineoplastic Agents; Bone Marrow Cells; Central Nervous System; Cytarabine; Disease Progression; Etoposide; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Mediastinum; Polyploidy; Prognosis; Stem Cell Transplantation; Tomography, X-Ray Computed | 2005 |
Clinical significance of development of Philadelphia-chromosome negative clones in patients with chronic myeloid leukemia treated with imatinib mesylate.
Topics: Acute Disease; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Clone Cells; Cytarabine; Disease Progression; Fatal Outcome; Fusion Proteins, bcr-abl; Granulocyte Colony-Stimulating Factor; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neoplastic Stem Cells; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Selection, Genetic; Vidarabine | 2005 |
Chronic myelogenous leukemia.
Topics: Algorithms; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Cell Transformation, Neoplastic; Chromosome Breakage; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Cytarabine; Cytogenetic Analysis; Disease Progression; Drug Interactions; Gene Fusion; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Interferons; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Pyrimidines; Recombinant Fusion Proteins; Remission Induction; Secondary Prevention; Translocation, Genetic; Transplantation, Homologous | 2005 |
Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cytarabine; Deoxycytidine; Dexamethasone; Disease Progression; Disease-Free Survival; Etoposide; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Prognosis; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2006 |
Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Clinical Trials, Phase III as Topic; Cytarabine; Disease Progression; Female; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Splenomegaly; Survival Analysis; Treatment Failure; Treatment Outcome | 2006 |
Progressive hepatic lymphoma successfully treated with regional chemotherapy through a hepatic artery catheter.
Topics: Aged, 80 and over; Catheterization, Peripheral; Chemotherapy, Cancer, Regional Perfusion; Cytarabine; Disease Progression; Hepatic Artery; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Liver Neoplasms; Male; Radiography | 2006 |
Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers, Tumor; Cytarabine; Disease Progression; Female; HLA Antigens; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Predictive Value of Tests; Proportional Hazards Models; Remission Induction; Solubility; Topotecan; Treatment Outcome; Vidarabine | 2007 |
Total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine as a conditioning regimen in allogeneic hematopoietic stem cell transplantation for advanced myelodysplastic syndrome: a single-institute experience.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Cytarabine; Disease Progression; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation | 2007 |
Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biliary Atresia; Carboplatin; Carmustine; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Immunocompromised Host; Immunosuppressive Agents; Liver Transplantation; Lymphoma, T-Cell, Peripheral; Lymphoproliferative Disorders; Melphalan; Mesna; Postoperative Complications; Prednisone; Radiotherapy, Adjuvant; Transplantation, Autologous; Vidarabine; Vincristine | 2008 |
[Early relapse of Burkitt's lymphoma with t(8;14) and t(14;18) after rituximab-combined CODOX-M and IVAC therapy].
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 8; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Etoposide; Fatal Outcome; Female; Humans; Ifosfamide; Methotrexate; Recurrence; Remission Induction; Rituximab; Translocation, Genetic; Vincristine | 2007 |
Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Progression; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Histiocytes; Humans; Middle Aged; Prednisone; Retroperitoneal Neoplasms; Sarcoma; Thalidomide; Vincristine | 2007 |
Management of acute myeloid leukaemia--5 years experience at Armed Forces Bone Marrow Transplant Centre, Rawalpindi.
Topics: Adolescent; Adult; Anthracyclines; Antineoplastic Agents; Child; Cytarabine; Disease Progression; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Military Medicine; Military Personnel; Pakistan; Retrospective Studies; Time Factors; Treatment Outcome; Tretinoin | 2007 |
Potential of dendritic-cell immunotherapy for relapse after allogeneic hematopoietic stem cell transplantation, shown by WT1 peptide- and keyhole-limpet-hemocyanin-pulsed, donor-derived dendritic-cell vaccine for acute myeloid leukemia.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Combined Modality Therapy; Cytarabine; Daunorubicin; Dendritic Cells; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Hemocyanins; Humans; Immunosuppressive Agents; Immunotherapy, Active; Leukemia, Myelomonocytic, Acute; Living Donors; Middle Aged; Peptide Fragments; Phosphoproteins; Salvage Therapy; Siblings; Transplantation, Homologous; Viral Matrix Proteins; WT1 Proteins | 2008 |
High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease Progression; Etoposide; Female; Humans; Immunoblastic Lymphadenopathy; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Transplantation Conditioning; Treatment Outcome | 2008 |
Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Disease Progression; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Italy; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Methotrexate; Middle Aged; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Rituximab; Survival Rate; Thiotepa; Transplantation, Autologous; Treatment Outcome | 2008 |
Rapid progression of 'retinoic acid syndrome' in the hypogranular variant of acute promyelocytic leukaemia, despite treatment with dexamethasone and conventional chemotherapy.
Topics: Acute Kidney Injury; Adult; Antineoplastic Combined Chemotherapy Protocols; Cerebral Hemorrhage; Combined Modality Therapy; Cytarabine; Daunorubicin; Dexamethasone; Disease Progression; Fatal Outcome; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Renal Dialysis; Respiration, Artificial; Respiratory Insufficiency; Syndrome; Tretinoin | 1994 |
Double mutations of the N-ras gene in a patient with acute myelomonocytic leukemia.
Topics: Aclarubicin; Alleles; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 9; Codon; Cytarabine; Daunorubicin; Disease Progression; Doxorubicin; Etoposide; Fatal Outcome; Genes, ras; Genetic Vectors; Humans; Karyotyping; Leukemia, Myelomonocytic, Acute; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Point Mutation; Prednisolone; Vinblastine; Vincristine | 1995 |
Central nervous system granulocytic sarcoma in a patient with essential thrombocythemia.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blast Crisis; Bone Marrow; Busulfan; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease Progression; Epidural Space; Fatal Outcome; Frontal Bone; Humans; Leukemia, Myeloid; Leukemic Infiltration; Male; Methylprednisolone; Spinal Canal; Thrombocythemia, Essential | 1996 |
Idarubicin in combination with cytarabine and VP-16 in the treatment of post myelodysplastic syndrome acute myeloblastic leukemia (MDS-AML).
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease Progression; Disease-Free Survival; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction | 1995 |
Peripheral-T-cell lymphoma with hemophagocytic histiocytosis localised to the bone marrow associated with inappropriate secretion of antidiuretic hormone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Diseases; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Progression; Doxorubicin; Fatal Outcome; Female; Histiocytosis, Non-Langerhans-Cell; Humans; Ifosfamide; Inappropriate ADH Syndrome; Lymphoma, T-Cell, Peripheral; Methotrexate; Mitoguazone; Prednisone; Teniposide; Verapamil; Vincristine; Vindesine | 1995 |
Clonality switch in acute myeloid leukemia.
Topics: Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Clone Cells; Cyclophosphamide; Cytarabine; Daunorubicin; Disease Progression; Dosage Compensation, Genetic; Female; Hematopoiesis; Heterozygote; Humans; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Prednisolone; Remission Induction; Thioguanine; Vincristine | 1996 |
FLANG (fludarabine + cytosine arabinoside + novantrone + G-CSF) induces partial remission in lymphoid blast transformation of Ph+chronic myelogenous leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Bone Marrow Transplantation; Chromosome Aberrations; Combined Modality Therapy; Cytarabine; Disease Progression; Granulocyte Colony-Stimulating Factor; Humans; Hydroxyurea; Immunologic Factors; Interferon-alpha; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Remission Induction; Vidarabine | 1996 |
Exacerbation of hepatitis in hepatitis B carriers following chemotherapy for haematological malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carrier State; Chronic Disease; Cyclophosphamide; Cytarabine; Daunorubicin; Disease Progression; Doxorubicin; Etoposide; Female; Hepatic Encephalopathy; Hepatitis B; Humans; Leucovorin; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisone; Vincristine | 1996 |
Measurement of spontaneous and therapeutic agent-induced apoptosis with BCL-2 protein expression in acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Agents; Apoptosis; Bone Marrow; Cell Separation; Cytarabine; Daunorubicin; Disease Progression; Flow Cytometry; Gene Expression Regulation, Leukemic; Genes, p53; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid; Neoplasm Proteins; Neoplastic Stem Cells; Proto-Oncogene Proteins c-bcl-2; Reproducibility of Results; Sensitivity and Specificity; Tumor Cells, Cultured | 1997 |
Functional P-gp expression in multiple myeloma patients at primary diagnosis and relapse or progressive disease.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bence Jones Protein; beta 2-Microglobulin; C-Reactive Protein; Cytarabine; Dexamethasone; Disease Progression; Disease-Free Survival; Humans; Immunoglobulin G; Immunoglobulin M; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Recurrence; Survival Rate; Vincristine | 1997 |
A rare atypical myeloproliferative-disorder-like hemopathy with marked dysplasia, peripheral dominant myeloblast proliferation and extramedullary hematopoiesis was converted into typical acute myeloid leukemia with an interval of complete hematological re
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Disease Progression; Hematopoiesis, Extramedullary; Humans; Leukemia, Myeloid; Male; Mercaptopurine; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Prednisolone; Preleukemia; Remission Induction | 1998 |
Extramedullary involvement in patients with acute promyelocytic leukemia: a report of seven cases.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Brain Neoplasms; Cytarabine; Daunorubicin; Disease Progression; Fatal Outcome; Female; Gene Amplification; Gene Rearrangement; Humans; Idarubicin; Immunophenotyping; Leukemia, Promyelocytic, Acute; Lymph Nodes; Male; Middle Aged; Neoplasm Recurrence, Local; Polymerase Chain Reaction; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Skin Neoplasms; Translocation, Genetic; Tretinoin | 1998 |
Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Bone Marrow Purging; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease Progression; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Length of Stay; Leukemia, Myeloid; Male; Mechlorethamine; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Neoplastic Stem Cells; Pilot Projects; Platelet Transfusion; Recurrence; Remission Induction; Risk; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vidarabine | 1999 |
Long-term molecular remission in promyelocytic transformation of myeloproliferative disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Cytarabine; Daunorubicin; Disease Progression; Etoposide; Female; Humans; Idarubicin; Karyotyping; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Polycythemia Vera; Preleukemia; Prognosis; Remission Induction; Thrombocythemia, Essential; Thrombophilia; Translocation, Genetic; Tretinoin | 1999 |
Quantification of JC virus DNA in the cerebrospinal fluid of patients with human immunodeficiency virus-associated progressive multifocal leukoencephalopathy--a longitudinal study.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytarabine; Disease Progression; DNA, Viral; Drug Therapy, Combination; Humans; Immunization, Passive; Interferon-gamma; JC Virus; Leukoencephalopathy, Progressive Multifocal; Longitudinal Studies; Male; Polymerase Chain Reaction; Salvage Therapy; Viral Load; Virus Shedding | 1999 |
Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Melphalan; Methotrexate; Middle Aged; Mitoxantrone; Remission Induction; Survival Analysis; Treatment Outcome; Vincristine | 2000 |
Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carmustine; Cataract; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease Progression; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Infections; Life Tables; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Prognosis; Remission Induction; Retrospective Studies; Survival Analysis; Sweden; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 2000 |
Current treatment approaches for neoplastic meningitis: nursing management of patients receiving intrathecal DepoCyt.
Topics: Antimetabolites, Antineoplastic; Brain Neoplasms; Combined Modality Therapy; Cytarabine; Delayed-Action Preparations; Disease Progression; Education, Nursing, Continuing; Humans; Injections, Spinal; Meningeal Neoplasms; Meninges; Oncology Nursing; Patient Education as Topic; Quality of Life | 2000 |
Biochemical markers of bone turnover following high-dose chemotherapy and autografting in multiple myeloma.
Topics: Adult; Aged; Alkaline Phosphatase; Amino Acids; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Remodeling; Bone Resorption; Carmustine; Clodronic Acid; Combined Modality Therapy; Cytarabine; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Isoenzymes; Male; Melphalan; Middle Aged; Multiple Myeloma; Osteoclasts; Peptide Fragments; Podophyllotoxin; Procollagen; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2000 |
Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (>/=60 years) with non-Hodgkin's lymphoma: comparison with patients <60 years treated within the same protocol.
Topics: Adolescent; Adult; Age Factors; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Disease Progression; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Infections; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Survival Rate; Time Factors; Transplantation Conditioning | 2000 |
Distinct radiochemotherapy protocols differentially influence cellular proliferation and expression of p53 and Bcl-2 in glioblastoma multiforme relapses in vivo.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers; Brain Neoplasms; Cell Division; Chemotherapy, Adjuvant; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Disease Progression; Female; Gene Expression Regulation, Neoplastic; Genes; Genes, bcl-2; Glioblastoma; GTP-Binding Proteins; Humans; Ki-67 Antigen; Life Tables; Lomustine; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Nimustine; Protein Glutamine gamma Glutamyltransferase 2; Proto-Oncogene Proteins c-bcl-2; Radiotherapy, Adjuvant; Survival Analysis; Teniposide; Transglutaminases; Tumor Suppressor Protein p53 | 2000 |
Primary central nervous system lymphoma in childhood presenting as progressive panhypopituitarism.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Cytarabine; Diabetes Insipidus; Disease Progression; Doxorubicin; Dwarfism, Pituitary; False Negative Reactions; Genetic Predisposition to Disease; Human Growth Hormone; Humans; Hydrocortisone; Hypopituitarism; Hypothyroidism; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Male; Methotrexate; Pituitary Hormones; Pituitary Neoplasms; Prednisone; Remission Induction; Vincristine | 2001 |
Temporary response of localized intracranial mast cell sarcoma to combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Daunorubicin; Disease Progression; Etoposide; Fatal Outcome; Female; Headache; Humans; Immunologic Factors; Injections, Spinal; Interferon alpha-2; Interferon-alpha; Mast-Cell Sarcoma; Nausea; Neoplasm Recurrence, Local; Palliative Care; Papilledema; Parietal Lobe; Prednisolone; Radioisotope Teletherapy; Recombinant Proteins; Remission Induction; Supratentorial Neoplasms; Temporal Lobe; Treatment Failure; Vomiting | 2001 |
[Low-dose cytosine-arabinoside (Ara-C) therapy for chronic myeloid leukemia].
Topics: Adult; Antimetabolites, Antineoplastic; Cytarabine; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Time Factors; Treatment Outcome | 2001 |
Cytarabine added to interferon improves the cost-effectiveness of initial therapy for patients with early chronic phase chronic myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Cytarabine; Decision Trees; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Markov Chains; Middle Aged; Quality of Life; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2001 |
Involvement of the NUP98 gene in a chromosomal translocation t(11;20)(p15;q11.2) in a patient with acute monocytic leukemia (FAB-M5b).
Topics: Aclarubicin; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 20; Combined Modality Therapy; Cytarabine; Disease Progression; Fatal Outcome; Female; Hemorrhage; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Monocytic, Acute; Mercaptopurine; Middle Aged; Neoplasm Proteins; Nuclear Pore Complex Proteins; Prednisolone; Sepsis; Translocation, Genetic | 2001 |
Myelodysplastic syndrome progresses rapidly into erythroleukemia associated with synchronous double cancers of the stomach and the papilla of Vater.
Topics: Aclarubicin; Adenocarcinoma; Aged; Ampulla of Vater; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cholestasis, Extrahepatic; Chromosome Aberrations; Chromosome Disorders; Common Bile Duct Neoplasms; Cytarabine; Disease Progression; Granulocyte Colony-Stimulating Factor; Humans; Karyotyping; Leukemia, Erythroblastic, Acute; Male; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Pancytopenia; Stomach Neoplasms | 2001 |
Cocaine-contaminated allogeneic bone marrow transplantation.
Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Bone Marrow Transplantation; Cocaine-Related Disorders; Cytarabine; Daunorubicin; Disease Progression; Fatal Outcome; Female; Graft Survival; Humans; Immunosuppression Therapy; Leukemia, Myeloid, Acute; Male; Marijuana Abuse; Middle Aged; Recurrence; Salvage Therapy; Thrombocythemia, Essential; Tissue and Organ Procurement; Tissue Donors; Transplantation, Homologous | 2001 |
Prognosis of elderly patients with acute myelogenous leukemia: analysis of 126 AML cases.
Topics: Acute Disease; Age Factors; Aged; Allopurinol; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cholinesterases; Cytarabine; Daunorubicin; Disease Progression; Female; Humans; Japan; Karyotyping; Leukemia, Myeloid; Life Tables; Male; Mercaptopurine; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Prognosis; Remission Induction; Risk Factors; Survival Analysis; Survival Rate | 2002 |
Cutaneous pleomorphic T-cell lymphoma coexisting with myelodysplastic syndrome transforming into acute myeloid leukemia: successful treatment with a fludarabine-containing regimen.
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Contraindications; Cytarabine; Disease Progression; Granulocyte Colony-Stimulating Factor; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Lymphoma, T-Cell, Cutaneous; Male; Methotrexate; Neoplasms, Second Primary; Remission Induction; Skin Neoplasms; Vidarabine | 2002 |